ContextVision AB: Q1 interim report 2026 - Solid progress and disciplined execution in a stabilising market
Summary by AI BETAClose X
Q1 Highlights
- Continued execution in a stabilising market, with underlying revenue growth of approximately 7.4%.
- Announced strategic R&D collaboration with BeamWorks to advance AI-powered quantitative ultrasound imaging solutions.
- Continued progress in clinical development program at the University of Washington.
- Strengthened the leadership team with the appointment of Marco Marien Voormolen as Chief Technology Officer.
- Sustained strong customer engagement at ECR 2026, supporting an active pipeline of technical and commercial follow-up activities.
- Extended the ongoing share buyback program until May 11, 2026.
Q1 Financial Data
- Revenue of 28.5 MSEK (26.3), up 8.5%.
- EBITDA amounted to 2.8 MSEK (–1.7) with an EBITDA margin of 10.0% (–6.3).
- Adjusted EBITDA amounted to 5.8 MSEK (2.1) with an adjusted EBITDA margin of 20.5% (8.1).*
- Cash flow from operating activities was 4.3 MSEK (0.3).
- Earnings per share was 0.01 SEK (–0.04).
- Adjusted earnings per share was 0.05 SEK (0.01).*
* ContextVision adjusts for investments in Data Quality to facilitate analysis of the underlying business.
The investments amounted to 3.0 MSEK in Q1 2026.
Solid progress and disciplined execution in a stabilising market
The first quarter of 2026 reflects continued execution in a stabilising market, alongside solid progress toward data-driven quantitative imaging. As part of our ongoing development, we strengthened our leadership team with the appointment of Marco Marien Voormolen as Chief Technology Officer. In parallel, we announced a promising collaboration with BeamWorks – an important milestone supporting our long-term value creation ambitions.
Revenue for the first quarter of 2026 amounted to 28.5 MSEK (26.3), an increase of 8.5% compared to Q1 2025. During the first quarter, ContextVision refined its assessment of the timing of revenue recognition for certain customer contracts, impacting revenue recognition within the period. In addition, a translational FX effect of -5.7% had a negative impact on sales, corresponding to -1.3 MSEK. Everything considered, the positive effect from the updated assessment and the negative impact from FX largely offset each other, and we saw an underlying revenue growth of approximately 7.4% for the quarter in a cautiously stabilising market. In contrast to Q1 2025, which was significantly impacted by challenging market conditions, this quarter benefited from increased license sales and additional contracts signed with clients, contributing positively to performance.
Adjusted EBITDA came in at 5.8 MSEK (2.1), corresponding to a margin of 20.5% (8.1), excluding investments in Data Quality of 3.0 MSEK. The improvement in profitability reflects increased license revenues combined with disciplined cost control. At the same time, we maintained our investments in quantitative imaging, while a more efficient allocation of consultant resources contributed to overall lower R&D costs.
The global political environment continued to contribute to cautious healthcare investment decisions globally. Looking back, the Chinese ultrasound market declined by approximately 8.5% for the full year 2025. This development was primarily driven by nationwide changes in procurement processes, where purchasing has become increasingly centralised. As a result, procurement cycles have temporarily slowed, rather than reflecting a reduction in underlying demand. Despite this market development, ContextVision has continued to strengthen and expand its relationships with Chinese customers through ongoing discussion and collaborations, positioning ContextVision well to benefit as procurement activity normalises and delayed purchasing processes resume.
Recognising the importance of reinforcing relationships remains a priority in the current market environment. We actively participated in ECR 2026, where ContextVision held a broad range of meetings with partners and prospects within ultrasound and X-ray. These discussions confirmed continued demand for high diagnostic image quality, robust performance in complex cases, and workflow simplification. Overall, the event reinforced the strategic relevance of our image quality portfolio and resulted in an active pipeline of follow-up activities with defined technical and commercial actions for the coming months.
During the quarter, we also announced a strategic research and development collaboration with BeamWorks Inc. The collaboration brings together ContextVision’s expertise in ultrasound image processing with BeamWorks’ deep learning platform. The companies aim to conduct joint R&D projects to develop and commercialize ultrasound-based digital biomarkers that support point-of-care clinical decision-making. With ContextVision’s existing MASLD biomarker program and BeamWorks’ CadAI product line, we aim to accelerate innovation and enhance diagnostic accuracy.
Further supporting this development, Marco Marien Voormolen joined as Chief Technology Officer at the beginning of the year. His expertise will support the execution of our technology roadmap, enhance collaboration with OEM partners and the research community, and accelerate our expansion beyond image enhancement into new solution areas.
Looking ahead to the coming quarters, we will continue to execute on our priorities while capitalising on emerging opportunities in the market. As a continued sign of confidence in our capital structure and direction, during the quarter we extended our ongoing share buy-back program for a further two months until May 11, 2026, reflecting our commitment to delivering sustainable long-term value creation.
Dr. Dr. Gerald Pötzsch
Chief Executive Officer
For more information, please contact
Richard Hallström
Chief Financial Officer
richard.hallstrom@contextvision.com
About ContextVision
ContextVision is a software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.
Latest directors dealings
- 7 hours ago Savannah Energy
- 8 hours ago Buccaneer Energy PLC
- 8 hours ago Savannah Energy
- 8 hours ago Carclo
- 9 hours ago Schroder Japan Growth Fund